Matrix tablets based on a carrageenan with the modified-release of sodium riboflavin 5′-phosphate

Abstract

The focus of this work was to produce modified-release monolithic matrix tablets containing sodium riboflavin 5′-phosphate (vitamin B₂) as active pharmaceutical ingredient (API). Riboflavin 5′-phosphate is absorbed from the upper gastrointestinal tract by a specific transport mechanism. The aim of this work was the development of modified-release tablets from which most or the entire API can dissolve within 5 h. The dissolution was started in medium pH 1.2 (gastric juice) and finished in medium pH 4.5. The matrix former was iota-carrageenan combined with microcrystalline cellulose (MCC) and lactose in different ratios. Factorial design was used in this work so as to study the effects of the MCC/lactose ratio on the parameters of the tablets, and especially on the dissolution process. The dissolution data were subjected to statistical analysis, and the release profiles were fitted with different models. It was found that the MCC/lactose ratio influenced the quality of the tablets to a high degree. The Korsmeyer–Peppas model proved to characterize the total dissolution profile best, but fitting of the separate sections was also possible with a linear model.

• Factorial design
• iota-carrageenan
• monolithic matrix tablet
• statistical analysis

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.